英文字典中文字典


英文字典中文字典51ZiDian.com



中文字典辞典   英文字典 a   b   c   d   e   f   g   h   i   j   k   l   m   n   o   p   q   r   s   t   u   v   w   x   y   z       







请输入英文单字，中文词皆可：


请选择你想看的字典辞典：
单词字典翻译
kus查看　kus　在百度字典中的解释百度英翻中〔查看〕
kus查看　kus　在Google字典中的解释Google英翻中〔查看〕
kus查看　kus　在Yahoo字典中的解释Yahoo英翻中〔查看〕

安装中文字典英文字典查询工具!


中文字典英文字典工具:
选择颜色:
输入中英文单字

































































英文字典中文字典相关资料:


  • ESR1-mutated, ER+ HER2- mBC Treatment | ORSERDU® (elacestrant)
    INDICATION ORSERDU (elacestrant) is indicated for the treatment of postmenopausal women or adult men with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, ESR1 -mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy
  • ESR1-Mutated ER+ HER2- mBC Therapy - ORSERDU® (elacestrant)
    Evaluate ORSERDU®, a treatment option for ESR1-mutated, ER+ HER2- advanced or metastatic breast cancer following disease progression on endocrine therapy
  • ER+, HER2−, ESR1-mutated MBC | Inluriyo™ (imlunestrant)
    Inluriyo is an oral treatment designed * for ER+, HER2–, ESR1 -mutated metastatic breast cancer Inluriyo is a prescription medicine used to treat adults with advanced breast cancer or breast cancer that has spread to other parts of the body (metastatic) whose disease was previously treated with endocrine therapy
  • U. S. FDA approves Inluriyo (imlunestrant) for adults with ER+ . . .
    Inluriyo is a treatment for ER+, HER2–, ESR1 -mutated MBC Some breast cancers develop ESR1 mutations that can cause estrogen receptors to become overactive and drive cancer growth
  • FDA approves elacestrant for ER-positive, HER2-negative, ESR1 . . .
    On January 27, 2023, the Food and Drug Administration (FDA) approved elacestrant (Orserdu, Stemline Therapeutics, Inc ) for postmenopausal women or adult men with ER-positive, HER2-negative, ESR1
  • ORSERDU™ (elacestrant): The First and Only Therapy Indicated . . .
    ORSERDU (elacestrant) 345 mg tablets are indicated for the treatment of postmenopausal women or adult men with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, ESR1-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy Please see full Prescribing Information, including Patient Information
  • Real-World Outcomes of Elacestrant in ER+, HER2−,
    AbstractPurpose: The EMERALD trial led to the approval of elacestrant for estrogen receptor (ER)–positive, HER2-negative, estrogen receptor 1 (ESR1)–mutated advanced or metastatic breast cancer (mBC) with disease progression following at least one line of endocrine therapy (ET) Subgroup analyses provided evidence suggesting that elacestrant enables ET sequencing in the second line before
  • U. S. FDA approves Inluriyo (imlunestrant) for adults with ER+ . . .
    Inluriyo is a treatment for ER+, HER2–, ESR1-mutated MBC Some breast cancers develop ESR1 mutations that can cause estrogen receptors to become overactive and drive cancer growth
  • ELEVATE Trial: Elacestrant Combos Boost PFS in ER+ HER2 . . .
    Study Rationale In January 2023, the FDA approved elacestrant for the treatment of postmenopausal women or adult men with ER-positive, HER2-negative, ESR1 -mutated advanced or metastatic breast cancer with disease progression following at least 1 line of endocrine therapy 2





中文字典-英文字典  2005-2009